CASE REPORT

Acute interstitial nephritis with podocyte foot-process effacement complicating Plasmodium falciparum infection

Patrick J. Gleeson1,4*, John A. O'Regan1, Teresa McHale2, Helen Tuite3, Louise Giblin1 and Donal Reddan1

Abstract

Background: Malarial acute renal failure (MARF) is a component of the severe malaria syndrome, and complicates 1–5% of malaria infections. This form of renal failure has not been well characterized by histopathology.

Case presentation: A 44 year-old male presented to the emergency department with a 5-day history of fever and malaise after returning from Nigeria. A blood film was positive for Plasmodium falciparum. His creatinine was 616 µmol/L coming from a normal baseline of 89 µmol/L. He had a urine protein:creatinine ratio of 346 mg/mmol (4.4 g/L). He required dialysis. A renal biopsy showed acute interstitial nephritis with podocyte foot-process effacement. He was treated with artesunate and his renal function improved. At 1 year follow-up his creatinine had plateaued at 120 µmol/L with persistent low-grade proteinuria.

Conclusion: Acute interstitial nephritis and podocyte foot-process effacement might be under-recognized lesions in MARF. Studying the mechanisms of MARF could give insight into the immunopathology of severe malaria.

Keywords: Malarial acute renal failure (MARF), Acute interstitial nephritis, Minimal change disease (MCD), Podocyte, Severe malaria

Background

Acute renal failure complicates 1–5% of malaria infections and this syndrome is referred to as malarial acute renal failure (MARF). MARF is a criterion for severe malaria and its associated mortality rate is 15–45% [1, 2]. Plasmodium falciparum is nearly always the infecting pathogen in MARF; rarely, Plasmodium vivax has been implicated [2, 3]. MARF has not been well characterized by histopathological examination of renal biopsies. Sparse clinical and animal data suggest that the underlying renal pathologies include acute tubular necrosis (ATN), post-infectious glomerulonephritis and mesangio-proliferative glomerulonephritis [2, 4]. Acute interstitial nephritis (AIN) has only been described in animal models of malaria [2, 5]. Recognized pathogenic mechanisms of MARF include sequestration of parasitized erythrocytes in the renal microcirculation resulting in ATN [6], endothelial activation [7] and toxicity from free haemoglobin [8]. Proteinuria is a frequent feature of P. falciparum infection [9, 10] however, the lesions responsible for this are not clear, as electron microscopy studies of affected glomeruli have not been reported. Further delineating the mechanisms of MARF in humans could inform treatment strategies and improve our understanding of the inflammatory response to malaria, particularly in severe malaria. Here, a case of MARF with histologically proven eosinophilic AIN and podocyte foot-process effacement is reported.

Case

A 44 year-old male presented to the emergency department with a 5-day history of fever and malaise. He had recently returned to Ireland (his country of residence for 10 years) from Nigeria (his native country) after visiting friends and relatives, without taking malaria prophylaxis. He had a history of hypertension, for which he took...
ramipril, amlodipine and bendroflumethiazide throughout the previous year. There was no family history of renal disease. He reported having taken over the counter paracetamol during the 5 days prior to presentation, and a single 400 mg dose of ibuprofen on the day of presentation. Consumption of non-steroidal anti-inflammatory drugs (NSAIDs) beyond the day of presentation was repeatedly denied. He had not taken any other medications commonly associated with AIN such as beta-lactams, fluoroquinolones, sulfonamides or proton pump inhibitors prior to presentation.

On examination, he was euvoaemic, his blood pressure was 169/77 mmHg and he produced 1580 mls of dark urine during the first 24 h. Urinalysis revealed 4+ protein and 3+ blood. He did not have a rash and had no peripheral oedema.

Initial routine blood tests included creatinine 616 µmol/L (baseline 89 µmol/L, 5 months before presentation), haemoglobin 11.2 g/dL, platelet count 70 x 10^9/L, eosinophil count 0.1 x 10^9/L, serum albumin 26 g/L, total serum bilirubin 15 µmol/L and lactate dehydrogenase 960 U/L. A blood film was positive for *P. falciparum* with 0.4% parasitaemia. Initial urine protein–creatinine ratio was 346 mg/mmol (absolute proteinuria = 4448 mg/L).

Tests for HIV, HBV, HCV, ANA and ANCA were all negative. C3 was normal and C4 was low (0.09 g/L). His haptoglobin was low (0.24 g/L) and G6PD enzyme activity was normal. A renal ultrasound described diffusely echogenic kidneys with the right kidney measuring 130 mm and the left kidney measuring 143 mm.

A renal biopsy performed 10 days after presentation demonstrated acute interstitial nephritis with numerous eosinophils, particularly at the cortico-medullary junction (Fig. 1a). There was an absence of neutrophils or granulomas. Immunofluorescence staining showed no specific pattern of antibody deposition for standard antisera (anti-IgG, anti-IgA, anti-IgM, anti-C3, anti-kappa, anti-lambda, anti-fibrin were all negative). Interstitial fibrosis was minimal. Electron microscopy revealed podocyte foot-process fusion involving the majority of capillaries, and the majority of the surface of affected capillaries, with microvillous transformation of the podocyte cytoplasm (Fig. 1b).

The patient was treated for severe malaria with intravenous artesunate on day 1, followed by a further 3 days of artesunate and a further 7 days of oral doxycycline. He was also covered empirically with ceftriaxone. Intermittent haemodialysis was started on hospital-day 3, as renal function was not recovering and the patient developed symptoms of uraemia. He received five sessions of intermittent haemodialysis before regaining independent renal function (Fig. 2). At 1 year follow up his creatinine had plateaued around 120 µmol/L, with persistent proteinuria (protein:creatinine ratio 172 mg/mmol) after restarting ramipril, amlodipine and bendroflumethiazide.

**Discussion**

Two important renal lesions were identified in this patient with MARF; the presence of eosinophilic AIN explains the acute drop in glomerular filtration rate, and fusion of the podocyte foot-processes ("minimal change disease", MCD) explains the heavy proteinuria. The relationship between these two lesions is unclear, although they both likely arose through the same inflammatory process. Parasitic infections can have a causative role in both AIN [11] and MCD [12, 13] however, the two typically arise together in drug-induced disease [14, 15].

A critical point in this case is to discern whether the interstitial nephritis was triggered by a drug or by the infecting pathogen. The patient had normal renal function documented while taking his anti-hypertensives, and there was no relapse after re-challenge with these medications. His renal failure was well established at presentation and renal function began to improve during his admission, so the medications he received in hospital cannot be held accountable. The consumption of a non-steroidal anti-inflammatory drug (NSAID) mandates further discussion.
NSAID induced interstitial nephritis occurs 2 weeks to 18 months after initial exposure to the drug [15]. A lymphocytic interstitial infiltrate predominates and there can be associated glomerular changes, such as minimal change or membranous nephropathy. NSAID induced disease is not associated with typical stigmata of an allergic reaction such as fever, rash, eosinophilia or eosinophiluria, and the proteinuria typically remits on withdrawal of the offending drug [15, 16]. The patient was only exposed to an NSAID on the day of presentation, which was too soon to explain his acute kidney injury, the biopsy showed an eosinophilic infiltrate and he has persistent proteinuria, so the renal findings cannot be explained by his drug history, which was corroborated a number of different times by different doctors.

Reports of renal biopsies from patients with MARF are scarce and mostly originate from India [17, 18]. One biopsy series of 20 patients with MARF found either ATN, mesangioproliferative glomerulonephritis or a combination of both [17]. Prakash et al. [18] reported a series of 6 MARF biopsies which revealed 1 necrotising glomerulonephritis while the other five had ATN. Owl monkeys challenged with *P. falciparum* were found to have renal malaria antigen deposition and interstitial nephritis [5].

Many infective organisms have been associated with interstitial nephritis [19], including a case of AIN associated with *Babesia microti*, a protozoan closely related to *Plasmodium*. In this case the inflammatory infiltrate also contained eosinophils and there was focal podocyte foot-process effacement [20], very similar to the present case.

Proteinuria is not uncommon in malaria infection [9, 10]. Ehrich et al. [9] reported proteinuria in 44% of patients with *P. falciparum* infection ranging from 0.15 to 5 g/day; there were no accompanying renal biopsies and, based on urine electrophoresis, they concluded that both glomerular and tubular sources could account for the proteinuria. More recently Ogbadoyi et al. [10] reported from Nigeria that about 70% of malaria patients had proteinuria, typically without an associated rise in creatinine, but again without any renal biopsy to explain the source of proteinuria. The podocyte foot-process fusion seen on electron microscopy explains the severe proteinuria seen in this patient; a similar phenomenon, with or without AIN, could explain the glomerular proteinuria seen in some other patients with *P. falciparum* infection.

MARF is predominantly a disease of partially- or non-immune adults in low-transmission endemic regions [1]—a population found mostly in Asia, which explains the high representation of published case-series from this region. In Africa, home to the greatest burden of *P. falciparum*, malaria is overwhelmingly a disease of children, in whom MARF is unusual [21]. However, given the volume of children infected, malaria is still an important cause of paediatric AKI and paediatric dialysis in sub-Saharan Africa [22], and MARF appears to be on the increase among children [1]. Malaria was the third greatest cause of AKI and dialysis at a paediatric teaching hospital in Nigeria [22]. A limitation of resources in sub-Saharan Africa, precluding detailed histological renal investigation, may have led to under-recognition of AIN and MCD as complications of *P. falciparum* infection. Given its absence in Asian case-series however, AIN is unlikely to be a common cause of MARF.

People living in malaria endemic regions develop an asymptomatic, non-sterile immunity to malaria after repeated exposure to infection, known as “premunition” [23, 24]. It is in the parasite's interest not to kill
its host, and the development of severe malaria might result from a dysregulated immune response to the parasite rather than from parasite virulence [25, 26]. The highest incidence of imported malaria in Europe is amongst immigrants native to malaria-endemic regions that return after visiting friends and relatives (VFR) [27]. This group are less inclined to take malaria prophylaxis as they do not expect to succumb to malaria however, premunition wanes after about 1 year of non-exposure to malaria antigen [24, 28]. This partially-immune VFR group are less likely to develop severe malaria than their European-tourist counterparts [26] but, anecdotally, they tend to develop more severe illness than if they had not left the endemic zone. One possible explanation for this is that they lose immune-tolerance to malaria antigens. Regulatory T cells (Tregs) dampen the immune response to frequently encountered antigens, however memory Tregs have a shorter life-span than memory T helper cells and memory B cells [29]. Experimental evidence of regulation of the anti-malarial immune response by regulatory T cells is accumulating, and these effects may even be organ specific [30]. Interestingly, Treg deficiencies are seen in MCD and immune checkpoint-inhibitor drugs, which counteract immune-tolerance, have been reported to cause MCD [31]. The Th2 immune response and IL-13, which recruit eosinophils to the site of inflammation, have been incriminated in the immunopathology of MCD [13].

The patient had no prior history of renal failure associated with malaria infection, despite coming from an endemic-region. He could have suffered interstitial nephritis with associated podocyte foot-process effacement on this occasion due to a loss of tolerance to malaria, leading to an unbridled cell-mediated inflammatory response to Plasmodium falciparum antigen deposited in his kidney. Plasmodium falciparum antigen deposition in renal tubules has previously been described in a post-mortem study [5]. The local release of cytokines, such as IL-13, could have induced podocyte foot-process effacement or, conversely, an increased leak of antigens through the glomeruli could have triggered a tubulo-interstitial infiltrate.

The low level of C4 in this patient can be attributed to activation of the classical complement pathway by malaria infection [32] and the blood on the urine dipstick is explained by intravascular haemolysis.

Regarding potential treatment options, corticosteroids have been shown to accelerate the rate of recovery from AIN, however they have not been shown to improve long term outcome [33]. Corticosteroids were not given to this patient, as they may be deleterious in acute malaria infection [2]; instead, the underlying cause was targeted with artesunate [34].

**Conclusion**

The conclusion that this case of AIN was caused by *P. falciparum* infection is supported firstly by the biological precedent in animal models, secondly, because the natural history of the illness and all clinical features are best explained by the malaria infection and, thirdly, because NSAID induced nephropathy does not fit with the patient’s drug history, histology or outcome. The principles of managing MARF include effective treatment of the infection according to WHO guidelines [35], avoidance of nephrotoxins, optimization of volume status, and initiation of renal replacement therapy when clinically indicated.

Describing the underlying renal pathology found in MARF is important as it can inform treatment strategies and improve our understanding of immunopathology in severe malaria.

**Abbreviations**

MARF: malarial acute renal failure; AKI: acute kidney injury; ATN: acute tubular necrosis; AIN: acute interstitial nephritis; HIV: human immunodeficiency virus; HBV: hepatitis B virus; HCV: hepatitis C virus; ANA: anti-nuclear antibody; ANCA: anti-neutrophil cytoplasmic antibody; C3: complement component 3; C4: complement component 4; IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; MCD: minimal change disease; NSAID: non-steroidal anti-inflammatory drug; H&E: haematoxylin and eosin; VFR: visiting friends and relative.

**Authors’ contributions**

PJG wrote the first draft of the manuscript. PJG, JOR, TMcH, HT, LG and DR interpreted patient data regarding the diagnosis and contributed to the manuscript. JG, HT, LG and DR were involved in the clinical care of the patient. TMcH analysed and interpreted the renal biopsy. All authors read and approved the final manuscript.

**Author details**

1 Department of Nephrology, University College Hospital, Galway, Republic of Ireland. 2 Department of Pathology, University College Hospital, Galway, Republic of Ireland. 3 Department of Infectious Disease, University College Hospital, Galway, Republic of Ireland. 4 Immune Receptors and Renal Immunopathology, INSERM Unit 1149, Centre de Recherche sur l’Inflammation, Université Sorbonne Paris Cité, Paris, France.

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Contact the corresponding author for further information.

**Ethics approval and consent to participate**

Informed, signed consent was obtained from the patient to publish details about the case anonymously.

**Funding**

This work received no specific funding.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 23 March 2017   Accepted: 14 February 2019
Published online: 01 March 2019

References
1. Das BS. Renal failure in malaria. J Vector Borne Dis. 2008;45:83–97.
2. Barsoum RS. Malarial acute renal failure. J Am Soc Nephrol. 2000;11:2147–54.
3. Barsoum RS. Malarial nephropathies. Nephrol Dial Transplant. 1998;13:1588–97.
4. Boonpucknavong V, Sitprija V. Renal disease in acute Plasmodium falciparum infection in man. Kidney Int. 1979;16:44–52.
5. Nagatake T, Broderson JR, Tegoshi T, Collins WE, Aikawa M. Renal pathology in owl monkeys vaccinated with Plasmodium falciparum asexual blood-stage synthetic peptide antigens. Am J Trop Med Hyg. 1992;47:614–60.
6. Nguansangiam S, Day NP, Hien TT, Mai NT, Chaisri U, Riganti M, et al. A quantitative ultrastructural study of renal pathology in fatal Plasmodium falciparum malaria. Trop Med Int Health. 2007;12:1037–50.
7. Hanson J, Lee SJ, Hossain MA, Anstey NM, Charunwatthana P, Maude RJ, et al. Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study. BMC Med. 2015;13:122.
8. Pleves K, Royakkers AA, Hanson J, Hasan MM, Alam S, Ghose A, et al. Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria. Malar J. 2014;13:91.
9. Ehrich JH, Horstmann RD. Origin of proteinuria in human malaria. Trop Med Parasitol. 1985;36:39–42.
10. Ogbadoyi EO. Assessment of renal function in malaria patients in Minna, North Central Nigeria. Afr J Infect Dis. 2007;1:57–64.
11. Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Int. 2010;77:956–61.
12. Glassock RJ. Secondary minimal change disease. Nephrol Dial Transplant. 2003;18(Suppl 6):v52–8.
13. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change lesion. Clin J Am Soc Nephrol. 2017;12:332–45.
14. Russell W, Smith W. Clarithromycin-induced acute interstitial nephritis and minimal change disease. NDT Plus. 2009;2:382–3.
15. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563–72.
16. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:135–245.
17. Gupta B. Dilugric and non-dilugric acute renal failure in malaria in west zone of Rajasthan, India—a comparative study. J Acute Dis. 2012;1:100–6.
18. Prakash J, Gupta A, Kumar Q, Rout SB, Malhotra V, Srivastava PK. Acute renal failure in falciparum malaria—increasing prevalence in some areas of India—a need for awareness. Nephrol Dial Transplant. 1996;11:2414–6.
19. Kodner CM, Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am Fam Physician. 2003;67:2527–34.
20. Luciano RL, Moeckel G, Palmer M, Perazella MA. Babesiosis-induced acute kidney injury with prominent urinary macrophages. Am J Kidney Dis. 2013;62:801–5.
21. White N. Malaria. In: Farrar J, Hotze P, Junghans T, Kang G, Laloo D, White N, editors. Manson’s tropical diseases. 23rd ed. Edinburgh: Elsevier Ltd.; 2013. p. 532–600 (chapter 9).
22. Esezobor CI, Ladapo TA, Osinaike B, Lesi FE. Paediatric acute kidney injury in a tertiary hospital in Nigeria: prevalence, causes and mortality rate. PLoS ONE. 2012;7:e51229.
23. Trape JF, Tall A, Sokhna C, Ly AB, Diagne N, Ndiath O, et al. The rise and fall of malaria in a West African rural community, Diegro, Senegal, from 1990 to 2012: a 22 year longitudinal study. Lancet Infect Dis. 2014;14:476–88.
24. Perignon JL, Druilhe P. Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Mem Inst Oswaldo Cruz. 1994;89(Suppl 2):51–3.
25. Prakash D, Fesel C, Jain R, Cazenave PA, Mishra GC, Pied S. Clusters of cytokines determine malaria severity in Plasmodium falciparum-infected patients from endemic areas of Central India. J Infect Dis. 2006;194:198–207.
26. Pistone T, Dallal A, Mecchin M, Receveur MC, Malvy D. Epidemiology of imported malaria give support to the hypothesis of long-term semi-immunity to malaria in sub-Saharan African migrants living in France. Travel Med Infect Dis. 2014;12:48–53.
27. Behrens RH, Neave PE, Jones CO. Imported malaria among people who travel to visit friends and relatives: is current UK policy effective or does it need a strategic change? Malar J. 2015;14:149.
28. Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, Canque B, Legros F, et al. The Diegro project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg. 1994;51:123–37.
29. Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, Masters JE, et al. Human CD4+CD25hiFoxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest. 2006;116:2425–33.
30. Riley EM, Wahl S, Perkins DJ, Schofield L. Regulating immunity to malaria. Parasitol Today. 2006;22:35–49.
31. Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Fruh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer. 2016;16:6556.
32. Silver KL, Higgins SJ, McDonald CR, Kain KC. Complement driven innate immune responses to malaria: fueling severe malaria diseases. Cell Microbiol. 2010;12:1036–45.
33. Clarkson MR, Giblin L, O’Connell FP, O’Kelly P, Walsh E, Conlon P, et al. Malaria 2012: a 22 year longitudinal study. Lancet Infect Dis. 2014;12:476–88.
34. Dondorp AM, Fanello C, Hendriksen IC, Gomes E, Seni A, Chhaganal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–57.
35. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.